Oritavancin: One And Done Antibiotic Could Reduce MRSA



Methicillin-resistant Staphylococcus aureus (MRSA) has become the poster child for antibiotic resistance in large part because of a larger problem: patients tend to stop taking antibiotics once they feel better. In such instances, the surviving bacteria may become impervious to the drugs designed to fight them. 

A single-dose antibiotic could fix that and a new one, oritavancin, is as effective in the battle against stubborn skin infections as a twice-daily infusion given for up to 10 days, according to a recent large study.
The three-year study of oritavancin that encompassed two large clinical trials enrolling nearly 2,000 patients. Findings from the trials will be presented to the U.S. Food and Drug Administration as part of the drug's approval application but results for the first of the two clinical trials, which included 475 patients randomized to take the investigational drug, and 479 patients following a typical regimen of vancomycin, including two infusions a day, for seven to 10 days, are in the
New England Journal of Medicine (NEJM).
In the studies, the single intravenous dose of oritavancin was as effective as vancomycin in shrinking the size of the lesion and reducing fever. Both were also similar in rates of requiring a rescue antibiotic.
"The prolonged activity is what makes oritavancin distinctive," said G. Ralph Corey, M.D., a professor of medicine and infectious diseases at Duke University School of Medicine and lead author of the study published June 5, 2014, in the New England Journal of Medicine (NEJM). "This drug has a long half-life, which allows for a single-dose treatment."
The new antibiotic also performed similarly to vancomycin in reducing the area of the wound by 20 percent or more within the first 48-72 hours of treatment, and in curing the patients of infection, including those infected with MRSA.
"Having a single-dose drug could potentially prevent hospitalizations or reduce the amount of time patients would spend in the hospital," Corey said.

Source: Duke University Medical Center

Comments

Post a Comment

Popular posts from this blog

Fussy eaters: the favoured food of Salmonella

Image
As antibiotic resistance increases the search for new anti-bacterial treatments becomes more and more important. One way to design anti-bacterials is to find specific biochemical pathways that the bacteria require to survive, and develop drugs that block off these pathways. Some pathways are better targets than others and for  Salmonella bacteria it was thought that pathways dealing with nutrient metabolises would be a lost cause. Salmonella lives in the intestine, which hosts a whole variety of different nutrients, so surely preventing the bacteria from using a specific one wouldn’t cause them much undue distress. It’s been found, however, that as they grow and spread in the inflamed intestine the bacteria are heavily reliant on one particular nutrient: fructose-asparagine. The chemical structure of fructose-asparagine, image from the reference. The importance of fructose-asparagine metabolism was originally discovered during experiments desig
Read more

Timing is key for bacteria surviving antibiotics

For bacteria facing a dose of antibiotics, timing might be the key to evading destruction. In a series of experiments, Princeton researchers found that cells that repaired DNA damaged by antibiotics before resuming growth had a much better chance of surviving treatment. When antibiotics hit a population of bacteria, often a small fraction of "persister" cells survive to pose a threat of recurrent infection. Unlike bacteria with genetic resistance to antibiotics, evidence suggests that persisters stay alive in part by stalling cellular processes targeted by the drugs. In a new study, Princeton researchers examined a class of antibiotics that target bacterial DNA. In bacterial populations, some cells repair damaged DNA before resuming growth, and others resume growth before making repairs. The researchers found that those that make repairs before resuming growth generally are the ones that survive as persisters. The research advances a long-term goal to make
Read more

Nanoparticles derived from tea leaves destroy lung cancer cells: Quantum dots have great potential

Nanoparticles derived from tea leaves inhibit the growth of lung cancer cells, destroying up to 80% of them, new research by a joint Swansea University and Indian team has shown. The team made the discovery while they were testing out a new method of producing a type of nanoparticle called quantum dots. These are tiny particles which measure less than 10 nanometres. A human hair is 40,000 nanometres thick. Although nanoparticles are already used in healthcare, quantum dots have only recently attracted researchers' attention. Already they are showing promise for use in different applications, from computers and solar cells to tumour imaging and treating cancer. Quantum dots can be made chemically, but this is complicated and expensive and has toxic side effects. The Swansea-led research team were therefore exploring a non-toxic plant-based alternative method of producing the dots, using tea leaf extract. Tea leaves contain a wide variety of compounds, including
Read more